Treatments for stage B liver cancer
Transarterial chemoembolization (TACE) @(Model.HeadingTag)>
TACE is a treatment that blocks the blood supply to a liver tumour and delivers chemotherapy directly to the tumour. It is the standard treatment for people who have good liver function, have a good
Targeted therapy @(Model.HeadingTag)>
Targeted therapy uses drugs to treat specific molecules (such as proteins) on cancer cells or inside them. By targeting these molecules, the drugs stop the growth and spread of cancer cells while limiting harm to normal cells. The targeted therapy drugs used for stage B liver cancer are sorafenib (Nexavar) and lenvatinib (Lenvima).
Targeted therapy may be offered if you cannot have TACE because you have portal hypertension or portal vein thrombosis or if TACE did not work.
Radiation therapy @(Model.HeadingTag)>
The following radiation therapy treatments may be offered if you are not able to have TACE.
Transarterial radioembolization (TARE) is a treatment that blocks the blood supply to a liver tumour and delivers radiation directly to the tumour.
Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that delivers very focused beams of high-dose radiation to liver tumours.
Clinical trials @(Model.HeadingTag)>
American Cancer Society. Liver Cancer. 2015: http://www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.pdf.
Bruix J, Sherman M. AASLD Practice Guideline: Management of hepatocellular carcinoma: an update. 2010: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012.
National Cancer Institute. Adult Primary Liver Cancer Treatment (PDQ®) Health Professional Version. 2015: http://www.cancer.gov/cancertopics/pdq/treatment/adult-primary-liver/HealthProfessional/page1/AllPages.
National Comprehensive Cancer Network (NCCN). Hepatobiliary Cancers Version 2.2015. 2015: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, et al . Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Current Oncology. 2011: http://www.current-oncology.com/index.php/oncology/article/view/952/737.